(Q33658659)

English

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial (English)

1 reference

Europe PubMed Central

28 July 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

N C Tebbutt

1

1 reference

Europe PubMed Central

28 July 2017

M M Cummins

2

1 reference

Europe PubMed Central

28 July 2017

T Sourjina

3

1 reference

Europe PubMed Central

28 July 2017

A Strickland

4

1 reference

Europe PubMed Central

28 July 2017

G Van Hazel

5

1 reference

Europe PubMed Central

28 July 2017

V Ganju

6

1 reference

Europe PubMed Central

28 July 2017

D Gibbs

7

1 reference

Europe PubMed Central

28 July 2017

M Stockler

8

1 reference

Europe PubMed Central

28 July 2017

V Gebski

9

1 reference

Europe PubMed Central

28 July 2017

J Zalcberg

10

1 reference

Europe PubMed Central

28 July 2017

Australasian Gastro-Intestinal Trials Group

11

1 reference

Europe PubMed Central

28 July 2017

language of work or name

0 references

publication date

12 January 2010

1 reference

Europe PubMed Central

28 July 2017

British Journal of Cancer

1 reference

Europe PubMed Central

28 July 2017

102

1 reference

Europe PubMed Central

28 July 2017

3

1 reference

Europe PubMed Central

28 July 2017

475-481

1 reference

Europe PubMed Central

28 July 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605522

0 references

The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822950

21 June 2018

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822950

21 June 2018

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822950

21 June 2018

Cetuximab for the treatment of colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822950

21 June 2018

Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822950

21 June 2018

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822950

21 June 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822950

21 June 2018

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822950

21 June 2018

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822950

21 June 2018

Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822950

21 June 2018

Docetaxel administration schedule: from fever to tears? A review of randomised studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822950

21 June 2018

Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822950

21 June 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822950

21 June 2018

A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822950

21 June 2018

Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605522

21 January 2018

Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605522

21 January 2018

A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605522

21 January 2018

Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605522

21 January 2018

Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605522

21 January 2018

Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605522

21 January 2018

Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605522

21 January 2018

Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822950

30 October 2018

Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20068567

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20068567

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20068567

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20068567

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6605522

1 reference

Europe PubMed Central

28 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33658659&oldid=1584689710"